The U.S. Food and Drug Administration has cleared Siemens Healthcare’s SOMATOM computed tomography (CT) systems for low-dose lung cancer screening.
The company says it now offers the industry’s most comprehensive approach to low-dose lung cancer screening — both on all of Siemens’ new CT scanners sold as well as on the company’s installed base of non-end-of-support systems – using standard low-dose lung protocols that are already delivered on Siemens CT scanners. From the SOMATOM Scope 16-slice CT system to the ultra-premium SOMATOM Force, Siemens makes low-dose lung cancer screening broadly available to its customers.
“Lung cancer screening represents one of the most significant opportunities to improve population health through earlier detection and improved follow-up opportunities for high-risk patients,” said David Pacitti, president of Siemens Healthcare North America. “That’s why Siemens pursued the most expansive indication for lung cancer screening, bringing this valuable tool to all varieties of our current SOMATOM CT scanners.”
The indication for low-dose lung cancer screening is available for the following CT systems: SOMATOM Force, SOMATOM Definition Flash, SOMATOM Definition Edge, SOMATOM Definition AS/AS+, SOMATOM Perspective, SOMATOM Scope, and the SOMATOM Emotion 16.
